Clinical research
As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines.
Mallinckrodt’s experimental drug terlipressin hit the mark in a late-stage liver disease trial. Mallinckrodt said terlipressin met its primary endpoint in reversing three components of hepatorenal syndrome type 1.
In the trial, evinacumab showed a 49% decrease in LDL cholesterol from baseline compared to placebo, which showed a 2% increase.
For the second time in a Phase III trial, Lynparza met its endpoints as a potential first-line treatment for ovarian cancer.
Deciphera’s stock jumped from Monday’s close of $19.95 to $44.40 this morning after the company showed ripretinib provided 6.3 months of progression-free survival compared to one month from placebo.
Patients who took Taltz in the post-marketing study achieved higher rates of “complete skin clearance” in comparison to Tremfya as measured by PASI 100.
Coordination Pharmaceuticals Inc., a privately-held oncology drug development company announced that the first patient has been dosed in a Phase 1 study of CPI-200 in patients with advanced tumors.
Akari Therapeutics, plc announced new preclinical and human data demonstrating the potential benefits of the dual inhibition of complement (C5) and leukotriene (LTB4) pathways by nomacopan for the treatment of pemphigoid disease (PD).
Cytovation AS and Specialized Medical Services-oncology BV announce that SMS-oncology has been selected as the CRO to conduct the phase I/II clinical trial with CyPep-1 in patients with advanced solid cancers.
Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look.
PRESS RELEASES